LVLinos VandekerckhoveMD, PhDSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2016PI remain important options for first line | Linos Vandekerckhove, MD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2016HIV attachment Inhibitors - Educational lecture in collaboration with ESAR | Thomas Klimkait, MDView Slideset
CBCharles BoucherMD, PhDSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2016Maintenance Therapy - What is the scientific/ virological rational | Charles Boucher, MD, PhDView Slideset
PCPep CollMD, MSSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2016Roadblocks to implementation | Pep Coll, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2016Community perspective | Rebekah WebbView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2016(Abstract) HBsAg immune-escape Mutations and Stop-Codons, Circulating among European HBV-chronically infected patients can impact on HBV transmission and disease progression | Dr. L. ColagrossiView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2016(Abstract) Clinical impact of vaccine-escape HBsAg mutants in HBV-infected patients: high rate of atypical serological profiles and increased level of viremia and transaminases | Dr. R. SalpiniView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2016(Abstract) Immunosuppression-driven HBV Reactivation in Patients with Resolved HBV Infection Correlates with a Relevant Risk of Evolution Towards Active Chronic Infection and Death | Dr. A. BattistiView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2016(Abstract) Antiviral Activity of Tenofovir Alafenamide (TAF) against HIV-1 Subtypes and Emergence of K65R | Dr. C. CallebautView Slideset
VideoHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2016Session 7 DiscussionView Video
JVJens VerheyenMD, PhDVideoHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2016Improving PI drug resistance scores | Jens Verheyen, MD, PhDView Video
LVLinos VandekerckhoveMD, PhDVideoHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2016PI remain important options for first line | Linos Vandekerckhove, MD, PhDView Video
